Cargando…

Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy

OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receivin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suthepwanon, Apisada, Uttasri, Patcharin, Boonyagars, Lakkana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272631/ https://www.ncbi.nlm.nih.gov/pubmed/35225455 http://dx.doi.org/10.31557/APJCP.2022.23.2.445

Ejemplares similares

HIV-Associated Dementia: Associated Factors and Characteristics of Cognitive Domain Abnormalities in Elderly People Living with HIV Treated with Highly Active Antiretroviral Therapy
por: Boonyagars, Lakkana, et al.
Publicado: (2022)

Presentation, Clinical Characteristics, and Treatment Outcomes among Tuberculous Meningitis Patients with and Without HIV Infection at Vajira Hospital, Thailand: A Retrospective Cohort Study
por: Boonyagars, Lakkana, et al.
Publicado: (2021)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

Neutropenia: occurrence and management in women with breast cancer receiving chemotherapy
por: do Nascimento, Talita Garcia, et al.
Publicado: (2014)

Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma
por: Park, Jinyong, et al.
Publicado: (2012)

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
por: Baig, Hassam, et al.
Publicado: (2018)

Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases
por: Nordvig, Josefine, et al.
Publicado: (2018)

Pulmonary Infectious Complications in Children with Hematologic Malignancies and Chemotherapy-Induced Neutropenia
por: Voulgaridou, Aikaterini, et al.
Publicado: (2020)

Intensity and duration of neutropenia relates to the development of oral mucositis but not odontogenic infection during chemotherapy for hematological malignancy
por: Kishimoto, Megumi, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
por: Álvarez, José C., et al.
Publicado: (2021)

Bloodstream infection in pediatric patients with febrile neutropenia induced by chemotherapy
por: Lima, Mariana Antunes Faria, et al.
Publicado: (2023)

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
por: Álvarez, José C, et al.
Publicado: (2013)

Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy
por: Siegmund, Mira, et al.
Publicado: (2020)

Sepsis and neutropenia in hematological malignancies
por: Labiad, Y, et al.
Publicado: (2014)

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
por: Pfeil, Alena M, et al.
Publicado: (2014)

Prediction of Febrile Neutropenia after Chemotherapy Based on Pretreatment Risk Factors among Cancer Patients
por: Aagaard, Theis, et al.
Publicado: (2017)

Evaluation of Bloodstream Infections During Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience
por: Piukovics, Klára, et al.
Publicado: (2015)

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
por: Krzemieniecki, K., et al.
Publicado: (2013)

Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
por: Averin, Ahuva, et al.
Publicado: (2020)

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
por: Weycker, Derek, et al.
Publicado: (2015)

Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients With Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy
por: Xiao, Ai Tang, et al.
Publicado: (2020)

A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
por: Leon Rapoport, Bernardo, et al.
Publicado: (2023)

Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009)

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia
por: Li, Yanli, et al.
Publicado: (2018)

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
por: del Giglio, A, et al.
Publicado: (2008)

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003)

Outcome of septic shock in patients with malignancies and neutropenia
por: Furmanchuk, D
Publicado: (2005)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data
por: Knerr, Sarah, et al.
Publicado: (2017)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy
por: Hidaka, Takao, et al.
Publicado: (2001)

Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria
por: Salako, Omolola, et al.
Publicado: (2021)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia, Roberto, et al.
Publicado: (2016)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt, Jonathan, et al.
Publicado: (2015)

Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia
por: Tsyrkunou, Artsiom, et al.
Publicado: (2016)

Rare severe mycotic infections in children receiving empirical caspofungin treatment for febrile neutropenia
por: Yilmaz Karapinar, Deniz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3ssnislvldutk4f66n45d0fpjj